Literature DB >> 6181216

The reversibility of phenytoin-induced IgA deficiency.

N E Gilhus, J A Aarli.   

Abstract

Phenytoin has been shown to induce serum IgA deficiency in patients with epilepsy. We have followed 37 phenytoin-treated patients with reduced serum IgA concentrations for 2-7 years. All anti-epileptic drug treatment was withdrawn in 8 patients. Phenytoin was substituted by other anti-epileptic drugs in 13 patients. Sixteen patients received phenytoin unchanged. The mean serum IgA concentration increased from 0.14 g/l to 0.71 g/l in the patients off drug treatment, and from 0.20 g/l to 0.84 g/l in the patients changing to other drugs. The mean IgA concentration increased from 0.21 g/l to 0.37 g/l in the patients with phenytoin unchanged, due to the increase of the IgA levels in a few patients who initially showed a slightly depressed IgA concentration. The overall increase of IgA concentrations was significant. When tested separately in each patient group, the difference was significant for the patients off all drugs, and for those changing from phenytoin to other drugs. The IgM concentration increased significantly when all patients were considered together. This was due to the increase of IgM in the patients no longer receiving phenytoin therapy. Withdrawal of phenytoin did not influence the IgG concentrations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6181216     DOI: 10.1007/bf00313318

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  [Serum protein levels in healthy Japanese children, with special regard to 5 classes of immunoglobulin (author's transl)].

Authors:  T Toba; T Nishimuta; S Funabashi; M Adachi
Journal:  Rinsho Byori       Date:  1975-10

2.  Reversal of selective IgA deficiency in a child with juvenile rheumatoid arthritis after plasma transfusions.

Authors:  R E Petty; J T Cassidy; D B Sullivan
Journal:  Pediatrics       Date:  1973-01       Impact factor: 7.124

3.  Immunoglobulin levels and autoantibodies in epileptics on long-term anticonvulsant therapy.

Authors:  P Andersen; L Moseklide
Journal:  Acta Med Scand       Date:  1977-01

4.  The effect of chronic N-dipropylacetamide ("depamide") treatment on plasmatic immunoglobulins of epileptic patients.

Authors:  R Musolino; M Natoli; G Gallitto; L Morgante; S Serra; F Pisani; R Di Perri
Journal:  Acta Neurol (Napoli)       Date:  1980-04

5.  Immunodeficiency in epilepsy: a new view.

Authors:  A Fontana; P J Grob
Journal:  J Neurol       Date:  1979-01-05       Impact factor: 4.849

6.  Depression of immune competence by phenytoin and carbamazepine. Studies in vivo and in vitro.

Authors:  T C Sorrell; I J Forbes
Journal:  Clin Exp Immunol       Date:  1975-05       Impact factor: 4.330

7.  IgA deficiency, epilepsy, and hydantoin medication.

Authors:  A Fontana; P J Grob; R Sauter; H Joller
Journal:  Lancet       Date:  1976-07-31       Impact factor: 79.321

8.  Phenytoin, methylprednisolone sodium succinate and graft survival.

Authors:  S Speier; J M Bromberg; N Lempert
Journal:  J Pharmacol Exp Ther       Date:  1981-01       Impact factor: 4.030

9.  Anticonvulsant drugs and cancer. A cohort study in patients with severe epilepsy.

Authors:  S J White; A E McLean; C Howland
Journal:  Lancet       Date:  1979-09-01       Impact factor: 79.321

10.  Immunological aspects of epilepsy.

Authors:  J A Aarli; A Fontana
Journal:  Epilepsia       Date:  1980-10       Impact factor: 5.864

View more
  3 in total

Review 1.  Immunoglobulins in epilepsy.

Authors:  J A Aarli
Journal:  Springer Semin Immunopathol       Date:  1985

Review 2.  Immunological adverse effects of anticonvulsants. What is their clinical relevance?

Authors:  F De Ponti; S Lecchini; M Cosentino; C M Castelletti; A Malesci; G M Frigo
Journal:  Drug Saf       Date:  1993-03       Impact factor: 5.606

3.  Immunoglobulins in children with epilepsy: the Dutch Study of Epilepsy in Childhood.

Authors:  P M C Callenbach; C M Jol-Van Der Zijde; A T Geerts; W F M Arts; C A Van Donselaar; A C B Peters; H Stroink; O F Brouwer; M J D Van Tol
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.